- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Consumers favor DTC ads
Fifty-one percent of consumers report that prescription drug advertising keeps them informed of available treatments, according to a survey of 12,000 individuals conducted by The NPD Group, Port Washington, NY.
Fifty-one percent of consumers report that prescription drug advertising keeps them informed of available treatments, according to a survey of 12,000 individuals conducted by The NPD Group, Port Washington, NY.
"Consumers are telling us that they want to be more informed of treatment alternatives," said Fariba Zamaniyan, senior account manager of NPD PharmTrends. "This is evidenced by their positive response to prescription-branded drug ads."
Not all consumers agree that prescription drug advertising is beneficial. Thirty-eight percent of those interviewed feel that there is too much advertising for these products. One-third said that the advertisements are too confusing and that they would not like to see more prescription drug advertising in the future.
Sales and recall
"Consumers who are suffering from a disease or condition are more interested in what the prescription drug advertisements have to say," said Zamaniyan. "Therefore, we see a correlation between prescription sales and ad recall." According to NPD, drug sales have seen steady growth. The strongest year for direct-to-consumer prescription advertising was 1999, in which DTC ads helped drive prescription growth by 18%. In the year ending September 2000, sales growth remained brisk but was slightly less than the peak in 1999.
"With more 'blockbuster' brands going off-patent in the next few years, it will be more important than ever for drug manufacturers to raise awareness for existing and upcoming formulations," said Zamaniyan. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
